Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ironwood Pharmaceuticals, Inc.

http://ironwoodpharma.com

Latest From Ironwood Pharmaceuticals, Inc.

BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal

BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.

Commercial ImmunoOncology

Finance Watch: Inhibikase IPO Brought 2020 US Total To 87

Public Company Edition: The new year started with two companies signaling plans for significant near-term initial public offerings, following Inhibikase’s launch as the last IPO of 2020. Other recent financial highlights include layoffs at Calithera and Regenxbio’s $200m Zolgensma royalty sale.

Financing Business Strategies

Pneumagen Targeting The Human Glycome To Block Viral Entry

Emerging Company Profile: UK biotech Pneumagen expects to enter clinical studies in 2021 with a potential first-in-class glycan-targeted protein for preventing respiratory tract infections.

Infectious Diseases Financing

Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products

Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.

Growth Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Microbia, Inc.
UsernamePublicRestriction

Register